特瑞普利联合新辅助化疗对局部晚期食管癌患者程序性死亡受体1、程序性死亡受体配体1表达水平及术后生存情况的影响  

Effects of Toripali combined with neoadjuvant chemotherapy on PD-1,PD-L1 levels and postoperative survival in patients with locally advanced esophageal cancer

作　　者：刘芳[1] 董红雨 王叶琳 李青松 LIU Fang;DONG Hong-yu;WANG Ye-lin;LI Qing-song(Department of Western Medicine,Nanyang First People's Hospital,Henan 473000,China)

机构地区：[1]南阳市第一人民医院西药科,河南473000

出　　处：《中国卫生检验杂志》2023年第5期520-523,共4页Chinese Journal of Health Laboratory Technology

基　　金：河南省医学科技攻关计划项目(2018020227)。

摘　　要：目的 探究特瑞普利联合新辅助化疗对局部晚期食管癌患者程序性死亡受体1(PD-1)、程序性死亡受体配体1(PD-L1)表达水平及术后生存情况的影响。方法 选取2018年2月—2019年11月本院收治的86例局部晚期食管癌患者,按随机数字表法分为观察组和对照组各43例。对照组予以新辅助化疗,观察组加用特瑞普利。比较2组生活质量核心量表(QLQ-C30)评分、鳞状细胞癌抗原(SCC-Ag)、糖类抗原19-9(CA19-9)、癌胚抗原(CEA)、PD-1、PD-L1、胸苷激酶1(TK1)、血管内皮生长因子(VEGF)、增殖细胞核抗原(PCNA)水平、毒副反应率、中位生存期。结果 术后6周观察组QLQ-C30评分、SCC-Ag、CA19-9、CEA、PD-1、PD-L1、TK1、VEGF、PCNA表达水平较对照组低,中位生存期较对照组长(P<0.05),2组毒副反应率比较差异无统计学意义(P>0.05)。结论 特瑞普利联合新辅助化疗可抑制患者肿瘤生长,提高生存质量,延长生存时间。Objective This paper aims to investigate the effects of Toripali combined with neoadjuvant chemotherapy on the levels of programmed death receptor 1(PD-1) and programmed death receptor ligand 1(PD-L1) and postoperative survival in patients with locally advanced esophageal cancer. Methods From February 2018 to November 2019, 86 patients with locally advanced esophageal cancer were selected and divided into observation group and control group according to the random number table method, with 43 cases in each group. Neoadjuvant chemotherapy was given to the control group, and Toripali was added to the observation group. The core scale of quality of life(QLQ-C30), squamous cell carcinoma antigen(SCC-Ag), glycoside antigen 19-9(CA19-9), carcinoembryonic antigen(CEA), PD-1, PD-L1, thymidine kinase 1(TK1), vascular endothelial growth factor(VEGF), proliferative cell nuclear antigen(PCNA) levels, toxic side reaction rate, and median survival were compared. Results The levels of QLQ-C30, SCC-Ag, CA19-9, CEA, PD-1, PD-L1, TK1, VEGF, and PCNA in the observation group were lower than those in the control group at 6 weeks postoperatively, and the median survival was lower than that in the control group(P<0.05). There was no statistical significance on the difference of toxicity and side reaction rates between the two groups(P>0.05). Conclusion Toripali combined with neoadjuvant chemotherapy can inhibit tumor growth, improve quality of life, and prolong survival time.

关 键 词：特瑞普利 局部晚期食管癌 程序性死亡受体1 新辅助化疗 程序性死亡受体配体1 中位生存期 

分 类 号：R735.1[医药卫生—肿瘤]